Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
about
Recent advances in understanding and managing cholestasisNovel bile acid therapeutics for the treatment of chronic liver diseasesBile Acid Metabolism and Signaling in Cholestasis, Inflammation, and CancerPathogenesis of primary sclerosing cholangitis and advances in diagnosis and managementRole of the intestinal bile acid transporters in bile acid and drug dispositionCystic fibrosis related liver disease--another black box in hepatology.Clinical application of transcriptional activators of bile salt transporters.Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation.Protective Effects of Norursodeoxycholic Acid Versus Ursodeoxycholic Acid on Thioacetamide-induced Rat Liver Fibrosis24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in miceNuclear receptors as drug targets in cholestatic liver diseases.Primary sclerosing cholangitis: diagnosis, prognosis, and management.High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.Hepatic inflammation and progressive liver fibrosis in chronic liver disease.Treatment options for primary sclerosing cholangitis.Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis.Evolving concepts in primary sclerosing cholangitis.Primary sclerosing cholangitis: is any treatment worthwhile?Recent insights in primary sclerosing cholangitis.Molecular targets for the treatment of fibrosing cholangiopathies.Bile acid transporters and regulatory nuclear receptors in the liver and beyondPrimary sclerosing cholangitis: a review and update on therapeutic developments.Primary Sclerosing Cholangitis: Current and Future Management Strategies.Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis.Animal models in primary biliary cirrhosis and primary sclerosing cholangitis.Primary sclerosing cholangitis - the Norwegian experience.Primary biliary cirrhosis: safety and benefits of established and emerging therapies.Emerging treatments for primary sclerosing cholangitis.Management of cholestatic disease in 2017.Role of farnesoid X receptor in cholestasis.New therapeutic concepts in bile acid transport and signaling for management of cholestasis.Animal models of biliary injury and altered bile acid metabolism.The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver.High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?Ursodeoxycholic acid stabilizes the bile salt export pump in the apical membrane in MDCK II cells.Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis.Primary sclerosing cholangitis: diagnostic and management challenges.Bile acid metabolism in liver pathobiology.Primary Sclerosing Cholangitis
P2860
Q26748537-51CD2FB7-D5AC-4002-BD7C-4BE4142E8D43Q26748613-B231FFE2-9404-452C-A593-821BAAD04398Q26800206-81AB49E4-9C96-4487-9FEA-27FE72FC8D2CQ27015831-5BFE7615-93B0-4C2D-8B63-31ED91171734Q28299162-1709E946-6443-451F-B3B0-31F59DAC6FE0Q28655881-33AAA3A1-8CB7-40D5-A641-70F529D940DBQ33709930-8E85E2F0-BDE5-4F67-90A7-DB709F6B7590Q34043010-83E4E164-7EF0-4C3F-A1DF-BA7A2B8D0845Q34983463-C036EE46-30B8-491A-81E1-954050642DC3Q35201779-170AA1E5-115C-44A9-9440-BE100595CA8CQ35269164-582BDC41-AED2-4C1D-B7D8-4F4205ABBF87Q36786270-F793B63C-D5D6-4F00-AE64-57469619D716Q36955053-49A26CCA-754D-4D94-B891-3559CCE0FEDDQ37117971-059D6D7B-8839-46F2-BB1E-CDF40811BE30Q37629675-C7E981EF-ABA6-4F83-B949-AB3ED0AE956FQ37777156-A5884924-6018-4DD2-BD49-EF2ED692A9A2Q37866339-17A54D5B-DD61-41C9-9F1E-1A5957DF60A1Q37957967-01049831-97F7-4C59-9C89-E0C12FC93AA5Q37962395-C4EF640A-0BF6-4C9F-BD7F-2F3377368A5AQ38019989-F8E40C2D-3AB4-4EC4-998A-8FBA98EA5870Q38031095-72EB64F3-58EA-47AA-A499-376A458C658FQ38033967-73E8B344-FD01-48F8-A837-20FBAE0ECFBEQ38077820-81E10FAB-2E30-40BF-9871-A0E43AF79411Q38107484-5C497CA2-45E4-4549-9929-00B143462780Q38174167-DE09DB40-6303-4B08-B817-7D0B5A3521E2Q38244716-F634D076-57B3-4E77-B659-B5FA962AA8CBQ38417642-ACCE10FB-CB87-4412-85B8-A7E4DB7A671BQ38554677-AE1A349E-B4C7-429F-95A0-E219193A06AAQ38748384-9009B089-4318-4D48-962E-C70BE6C674D2Q38774857-A7B5983D-3E4A-40BE-A1D7-2A1F36F8FED9Q38887864-8BFF7073-CEDD-45FE-9715-398401738437Q39044702-D2B79109-B25D-4D53-A39B-8F1A6E0BD156Q39436033-AE4EE3CA-7470-4AC7-8E82-3388748D14C4Q39779007-5C48B333-1192-4891-A6DF-9F714BF7568DQ43284332-137C53C7-5347-4AA5-9EA2-A230613E67D2Q45125133-B3B9C1F0-2972-427D-BF1B-182E9AF78ED7Q45993134-179E6BDD-57CC-4DB9-A848-AB8430FF9100Q47112995-56476EDE-2355-499E-8248-502F53D98982Q47645986-F8DE75EC-5082-49EB-8E46-421AC4A0A977Q56442935-4625A0F8-19CF-4A5D-B022-D569CC6BA3FB
P2860
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Side chain structure determine ...... xycholic acid in Mdr2-/- mice.
@ast
Side chain structure determine ...... xycholic acid in Mdr2-/- mice.
@en
type
label
Side chain structure determine ...... xycholic acid in Mdr2-/- mice.
@ast
Side chain structure determine ...... xycholic acid in Mdr2-/- mice.
@en
prefLabel
Side chain structure determine ...... xycholic acid in Mdr2-/- mice.
@ast
Side chain structure determine ...... xycholic acid in Mdr2-/- mice.
@en
P2093
P2860
P50
P356
P1433
P1476
Side chain structure determine ...... xycholic acid in Mdr2-/- mice.
@en
P2093
Alan F Hofmann
Andrea Fuchsbichler
Carlo Spirli
Cord Langner
Dagmar Silbert
Emina Halilbasic
Hanns-Ulrich Marschall
Helmut Denk
Judith Gumhold
Mario Strazzabosco
P2860
P304
P356
10.1002/HEP.22891
P407
P577
2009-06-01T00:00:00Z